Galimedix, Inc. | Finanzwire

Basculer en Français

9473	Companies
185388	Keywords
117743	Articles
99274	Press releases

Home
Companies
Galimedix, Inc.

BRIEF

published on 03/24/2025 at 15:12, 8 months 11 days ago

Galimedix Therapeutics to Present Promising Preclinical Alzheimer’s Treatment

Preclinical Data Galimedix Therapeutics Neuroprotection Alzheimer's Treatment Amyloid-beta
PRESS RELEASE

published on 03/24/2025 at 15:07, 8 months 11 days ago

Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator in development for oral Alzheimer’s disease treatment at AD/PD™ 2025 Conference
Galimedix Therapeutics to present positive pre-clinical data with amyloid beta aggregation modulator for oral Alzheimer's disease treatment at AD/PD(TM) 2025 Conference

Alzheimer's Disease Galimedix Therapeutics Pre-clinical Data AD/PD 2025 Conference Aβ Aggregation Modulator
BRIEF

published on 12/23/2024 at 17:35, 11 months 12 days ago

Galimedix Begins Phase 2 Trial with GAL-101 Eye Drops for Dry AMD

Phase 2 Study Neuroprotection GAL-101 Dry AMD Geographic Atrophy
PRESS RELEASE

published on 12/23/2024 at 17:30, 11 months 12 days ago

Galimedix Therapeutics initiates pivotal Phase 2 study with GAL-101 eye drops in dry AMD
Galimedix Therapeutics initiates Phase 2 study with GAL-101 eye drops for dry AMD, aiming to slow geographic atrophy growth. Trial led by world-leading retina experts and funded by Théa Open Innovation

Galimedix Therapeutics Phase 2 Study GAL-101 Dry AMD Geographic Atrophy
BRIEF

published on 12/05/2024 at 13:33, 11 months 30 days ago

Galimedix Therapeutics Initiates Phase 1 Study with Oral GAL-101

Alzheimer's Disease Galimedix Therapeutics GAL-101 Dry AMD Phase 1 Study
PRESS RELEASE

published on 12/05/2024 at 13:28, 11 months 30 days ago

Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments

Galimedix Therapeutics Neurodegenerative Diseases GAL-101 Alzheimer's Phase 1 Study
BRIEF

published on 06/10/2024 at 14:05, 1 year 5 months ago

Galimedix Therapeutics Assembles Scientific Advisory Board for Phase 2 Study of GAL-101

Scientific Advisory Board Galimedix Therapeutics GAL-101 Phase 2 Clinical Study Dry AMD
PRESS RELEASE

published on 06/10/2024 at 14:00, 1 year 5 months ago

Galimedix Therapeutics establishes Scientific Advisory Board of renowned retina experts as company prepares to enter Phase 2 clinical study with GAL-101
Galimedix Therapeutics forms Scientific Advisory Board of retina experts to guide Phase 2 study with GAL-101 eye drops for dry AMD, addressing unmet medical need

Scientific Advisory Board Galimedix Therapeutics Phase 2 Study Dry AMD Retina Experts
BRIEF

published on 03/08/2024 at 10:05, 1 year 8 months ago

Galimedix Therapeutics Unveils Promising Data on Alzheimer’s Treatment at AD/PD™ 2024

Clinical Development GAL-201 Alzheimer’s Disease Neuroprotective Effects Cognitive Function
PRESS RELEASE

published on 03/08/2024 at 10:00, 1 year 8 months ago

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
Galimedix Therapeutics presents new scientific data at AD/PD(TM) 2024, showing neuroprotective effects of GAL-201 for Alzheimer’s disease treatment, targeting misfolded Aβ monomers to prevent toxic aggregation

Alzheimer's Disease Galimedix Therapeutics Neuroprotective Effects Scientific Data AD/PD 2024

Accesswire

Published on 12/05/2025 at 02:35, 5 hours 55 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 6 hours ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 7 hours 30 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 9 hours 25 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 9 hours 30 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 08:05, 25 minutes ago

Smartmi Unveils the Air Purifier 3: Powerful, Smart, and Stylish Air Care for Modern Homes
Published on 12/05/2025 at 08:01, 29 minutes ago

Original-Research: Warimpex Finanz- und Beteiligungsholding AG (von East Value Research GmbH ):
Published on 12/05/2025 at 08:01, 29 minutes ago

Custodian Property Income REIT plc: Interim results for the period ended 30 September 2025
Published on 12/05/2025 at 08:00, 30 minutes ago

Swiss Prime Site Solutions Investment Fund Commercial (SPSS IFC) approaches the 500-million mark ahead of listing
Published on 12/05/2025 at 08:00, 30 minutes ago

Custodian Property Income REIT plc: Share Buyback

Les Echos

Published on 12/04/2025 at 18:00, 14 hours 30 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 14 hours 45 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 14 hours 46 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 1 day 1 hour ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 14 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE